KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Accumulated Expenses: 2010-2025

Historic Other Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 14 years, with Sep 2025 value amounting to $12.1 million.

  • Nektar Therapeutics' Other Accumulated Expenses fell 32.55% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 32.55%. This contributed to the annual value of $14.5 million for FY2024, which is 42.84% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Other Accumulated Expenses is $12.1 million, which was down 21.78% from $15.4 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Other Accumulated Expenses ranged from a high of $20.0 million in Q3 2021 and a low of $6.9 million during Q3 2023.
  • Its 3-year average for Other Accumulated Expenses is $12.0 million, with a median of $11.8 million in 2025.
  • Per our database at Business Quant, Nektar Therapeutics' Other Accumulated Expenses plummeted by 54.73% in 2022 and then surged by 157.86% in 2024.
  • Nektar Therapeutics' Other Accumulated Expenses (Quarterly) stood at $15.5 million in 2021, then slumped by 54.73% to $7.0 million in 2022, then spiked by 44.48% to $10.1 million in 2023, then soared by 42.84% to $14.5 million in 2024, then crashed by 32.55% to $12.1 million in 2025.
  • Its Other Accumulated Expenses was $12.1 million in Q3 2025, compared to $15.4 million in Q2 2025 and $11.8 million in Q1 2025.